Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the cosmetic and health implications of hirsutism and highlights its potential link to serious underlying disorders, but it presents no new clinical findings.

This case series observed the efficacy of GnRH analogues in diagnosing and treating various forms of ovarian hyperandrogenism, illustrating their role in symptom management without surgery, particularly for benign conditions and refractory androgen excess.

This review explores the role of hyperandrogenism, including adrenal-derived 11-oxygenated androgen, in the development of polycystic ovarian syndrome and discusses potential therapeutic strategies targeting androgen excess, without reporting new clinical results.

In this study, prenatal androgen exposure was linked to altered sexual behaviors in both male and female mice, with specific effects on mounting and lordosis behaviors.

This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.

This paper discusses polycystic ovary syndrome with a focus on androgen excess as the primary symptom and notes that insulin resistance may contribute to it in many patients, but provides no new research findings.

This study found a high prevalence of clinical signs and functional disorders of androgen excess in premenopausal women, with idiopathic hyperandrogenism and idiopathic hirsutism rates similar to PCOS.

This review offers evidence-based recommendations for diagnosing and treating female pattern hair loss, emphasizing clinical assessment and starting treatment with minoxidil, while noting that measurement of certain hormones and vitamins is optional.

This study suggests that although the G972R variant of the IRS1 gene might increase AA excess risk in heterozygous carriers with CYP21 mutations, both variations play a limited role in PCOS development.

This study found that prenatal exposure to androgens caused long-lasting heart remodeling and left ventricular hypertrophy in female mice offspring, suggesting potential cardiac risks for daughters of mothers with PCOS.

This study found that the N363S variant of the glucocorticoid receptor was rare among women with PCOS and did not significantly contribute to genetic risk for PCOS or adrenal androgen excess.

This review discusses potential treatments for androgen excess in polycystic ovary syndrome and reports no new findings, emphasizing the importance of individualized antiandrogenic management to minimize side effects.

This case report discusses a postmenopausal woman whose hyperandrogenism and metabolic symptoms improved significantly after the surgical removal of an ovarian Leydig cell tumor, confirmed post-operatively.

This case report describes a 23-year-old woman with an adult granulosa cell tumor of the ovary, whose symptoms and hormone levels improved significantly after surgical removal of the tumor.

This review discusses the hypothesis that polycystic ovary syndrome may originate in fetal life due to prenatal androgen exposure, but reports no new clinical results.

This study found that one year of antiandrogen treatment with spironolactone significantly decreased bone mineral density in young women with androgen excess.

This study found that higher BMI in PCOS patients at a Chinese clinic was associated with functional disorders of androgen excess, suggesting BMI may predict hyperandrogenism in this population.

This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.

In this study, polycystic ovary syndrome was the most prevalent cause of androgen excess, and suppressive hormonal therapy improved hirsutism, menstrual dysfunction, and acne in most patients, though side effects were common.

This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.

This study reported that classic anovulatory PCOS was the most common androgen excess disorder, followed by mild ovulatory PCOS and idiopathic hyperandrogenism, among patients evaluated for clinical hyperandrogenism.

This study found that women with polycystic ovary syndrome have higher rates of nonalcoholic fatty liver disease, with androgen excess contributing to the risk.

This article outlines the clinical features, evaluation, and treatment strategies for androgen excess in polycystic ovary syndrome, highlighting important diagnostic and management approaches but reporting no new research results.

This review examines the evaluation and management of hirsutism and hyperandrogenism in postmenopausal women and reports no new clinical findings.

This article reviews dietary recommendations for managing polycystic ovary syndrome and provides evidence that diet changes can improve the androgen profile in affected women, but it reports no new clinical results.

This article reviews androgen excess and cardiometabolic risks in women, highlighting increased cardiovascular disease risk in those with polycystic ovary syndrome, but reports no new clinical results.

This study suggests that acne is often associated with hyperandrogenemia in women, contradicting previous recommendations that acne is not linked to androgen excess disorders.

This paper reviews the endocrinological aspects of hirsutism, focusing on the role of androgens in excessive hair growth and the related disorders, without presenting new findings.

This review outlines a diagnostic approach for identifying non-PCOS pathology in women with androgen excess, emphasizing the importance of clinical history and biochemical phenotyping but reports no new clinical results.

This review discusses hormonal changes during menopause, emphasizing the relative androgen excess and the role of insulin resistance, and reports no new clinical findings.